**Inclusion criteria:**

hemoglobin (Hb) ≥ 80g/L,

neutrophilic granulocyte (ANC) ≥ 1.5×109/L,

platelet count (PLT) ≥ 80×109/L,

serum creatinine (Cr) ≤ 1.5× normal upper limit (ULN) or creatinine clearance (CCr) ≥ 60mL /min,

blood urea nitrogen (BUN) ≤ 2.5× normal upper limit (ULN),

total bilirubin (TB) ≤ 1.5×ULN, albumin (ALB) ≥ 25 g/L,

aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN or ALT and AST ≤ 5×ULN if accompanied by liver metastases.

Patients included in the tumor assessment need radiographic measurable disease, with at least one lesion that could be accurately measured according to response evaluation criteria in solid tumors (RECIST) version 1.1. Otherwise, the patients can only be included in the safety assessment.

**Exclusion criteria:**

pregnant or lactating women,

patients accepted prior anti-tumor treatments within 21 days prior to enrolment,

uncontrolled diseases in major systems,

unable to take oral drugs,

symptoms of brain metastases cannot be controlled and treated within 2 months,

major surgery or trauma and/or bleeding or bleeding episodes greater than the Common Terminology Criteria for Adverse Events (CTCAE) grade 3 within 28 days,

venous thromboembolism within 6 months or any major vascular event,

any serious unhealed wound, ulcer or fracture.

Patients who participated in other anti-tumor clinical trials within 4 weeks or had any conditions that might prejudice the subject or failed to meet the requirements of the subject, were also excluded.